Cellbion

308430

Company Profile

  • Business description

    Cellbion is a radiopharmaceutical innovation engaged in the development and commercialization of radioligand therapies to address unmet medical needs, focusing on improving patient outcomes and advancing healthcare through groundbreaking research and cutting-edge technology. Its pipeline products targeted indications are Prostate Cancer radiotherapy, Solid Tumors Diagnosis, Multiple Cancer types, and Others.

  • Contact

    103, Daehak-ro
    6th Floor
    Jongno-gu
    Seoul03080
    KOR

    T: +82 27433311

    http://www.cellbion.co.kr

  • Sector

    Healthcare

    Stock type

    Defensive

  • Industry

    Biotechnology

    Fiscal Year End

    31 December 2025

    Employees

    43

Stocks News & Analysis

stocks

Unconventional wisdom: Are dividends the answers?

As investors toil in complexity the obvious solution may be the right one.
stocks

Netflix: A business that’s nearly flawless

Streaming giant’s stellar results had areas of softness; currency tailwinds drive guidance raise.
stocks

Trump’s US dollar assault is fuelling CBA’s rise

A recent $1 billion investment in CBA by Texas based fund manager expresses concern for the outlook of the USD.

Morningstar Investment Ideas

Markets

Index
Last price
Change
% Change
All Ordinaries8,934.3045.10-0.50%
CAC 407,834.5816.300.21%
DAX 4024,217.5078.43-0.32%
Dow JONES (US)44,812.17118.260.26%
FTSE 1009,120.3118.06-0.20%
HKSE25,388.35278.83-1.09%
NASDAQ21,139.9782.010.39%
Nikkei 22541,456.23370.11-0.88%
NZX 50 Index12,853.4648.330.38%
S&P 5006,388.4925.140.40%
S&P/ASX 2008,666.9042.50-0.49%
SSE Composite Index3,593.6612.07-0.33%

Market Movers